Intelligence · Clinical Pipeline
Théa Pharma Ireland Pipeline
All ClinicalTrials.gov programs at Théa Pharma Ireland — phase, modality, and trial IDs.
- Programs
- 4
Quick answer
Théa Pharma Ireland has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets
Verona Pharma Ireland Limited
patients with secondary progressive MS
1 trial -
Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets, Mayzent 1 mg film-coated tablets, BAF312, BAF312, BAF312
Verona Pharma Ireland Limited
Active progressive multiple sclerosis course after an initial relapse clinical course
1 trial -
Zaredrop 75 mg/ml soluzione orale, Laroxyl 40 mg/ml gocce orali soluzione, FLUOXETINA DOC Generici 20 mg/5 ml Soluzione orale, Zoloft 20 mg/ml concentrato per soluzione orale, Brintellix 20 mg/ml oral drops, solution, Daparox 33,1 mg/ml, gocce orali, soluzione., CITALOPRAM ABC 40 mg/ml gocce orali, soluzione, ESCITALOPRAM DOC 20 mg/ml gocce orali, soluzione
Verona Pharma Ireland Limited
Patients with currently remitted depressive disorders.
1 trial -
Zeposia 0.92 mg hard capsules
Verona Pharma Ireland Limited
Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
1 trial
Frequently asked questions
How many pipeline programs does Théa Pharma Ireland have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs